Axens’ Paramax Technology Suite has been finalised by China’s Cnooc Huizhou Petrochemical Company for expanding its petrochemical complex. On completion of the project, the new complex is expected to produce 1,500,000 tonnes per year of para-xylene in a single train.

To fight the global pandemic of Covid 19 in the USA, Ineos has built two new hand sanitiser facilities in Arkansas and Pennsylvania. Both the plants are expected to produce 1 million bottles of sanitiser each per month in order to meet the shortage requirements.

AGC Pharma Chemicals Europe aims to increase pharmaceutical production capacity by 1.3 times that of the current level with this expansion. A new R&D facility is also expected to be constructed as a part of this project.

The South African Government has restricted port operations amidst the global pandemic of Covid-19. This has resulted in force majeure by Tata Chemicals South Africa for all bulk shipments of soda ash to South Africa.

Evonik has become the maiden company across the globe to launch a 3D-printable Peek (polyether ether ketone) filament as an implant-grade material for medical applications. The Peek filament is based on a highly viscous and high-performance polymer from Evonik.

Amidst the global pandemic of Covid-19, Exxon Mobil has modified its facilities in Louisiana, USA to produce an initial 160,000 gallons of medical grade sanitiser which will be donated to healthcare professionals to fight the deadly Coronavirus.

The new polyethylene unit (PE3) is expected to produce 270,000 tonnes of modern high-density polyethene granulate per year. The PE3 facility has been awarded the highest investment ever in the history of Czech Republic’s chemical industry.

The Institute for Bioplastics and Biocomposites forecasts a global production capacity of 4,3 million tons of bioplasics in 2022 — a real growth market. A US bioplastic resin provider wants to be part of this success story and invested in a tailor made production plant. For the challenging handling and processing of the natural raw materials they found in Azo the right partner.

With this mega investment, Sumitomo Chemical intends to make use of synthetic biology to develop innovative and high functional products and processes which are difficult to manufacture through chemical synthesis. The investment will also enable the firm to strengthen its business alliance with Conagen.

The aim of the ‘Macbeth’ project is to develop a new process for catalytic synthesis with appropriate separation equipment in a single, highly efficient catalytic membrane reactor. The project brings together 24 partners with expertise in the field. The EU has offered around 18 million dollars for this project.